Atavistik Bio

The company is a team of drug developers working to bring therapies to patients with significant unmet medical needs.

Atavistik Bio is a clinical-stage biotechnology company developing allosteric therapeutics to selectively modulate disease-causing proteins, with potential to treat serious diseases.

Atavistik Bio announces a research collaboration with Roche to develop allosteric small molecules for cardiovascular, renal and metabolic diseases. The agreement includes a $70 million upfront payment, potential milestone payments and royalties.

Sep 2026 · Atavistik BioNews article

Atavistik Bio joins the Cure HHT Clinical Trial Network to support development of ATV-1601 for hereditary hemorrhagic telangiectasia. The company also reports activating the first site in its Harmony-HHT Phase 1/2 study at Massachusetts General Hospital.

Jul 2026 · Atavistik BioNews article

Atavistik Bio announces U.S. FDA clearance of its investigational new drug application and Fast Track designation for ATV-1601, which is being studied as a treatment for hereditary hemorrhagic telangiectasia (HHT). The clearance supports a randomized Harmony-HHT Phase 1/2 study in people with moderate to severe HHT.

Jun 2026 · Atavistik BioNews article

Atavistik Bio closes a $40 million extension to its Series B financing, bringing total proceeds from the round to $160 million. RA Capital joins as a new investor, and the proceeds are intended to advance the company's HHT and myeloproliferative-neoplasm programs.

Mar 2026 · Atavistik BioNews article